

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE THREE MONTHS ENDED 30th JUNE 2018

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

Particulars	Three Months Ended			Financial Year Ended
	30.06.2018	31.03.2018	30.06.2017	31.03.2018
	(1)	(2)	(3)	(4)
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	INR In Lakhs			
Income:				
I Revenue from operations	12,516.28	11,044.13	10,189.20	42,657.39
II Other income Including dividend/share of profit from subsidiary/LLP	1,805.49	306.83	386.21	2,331.33
III Total Income (I+II)	14,321.77	11,350.96	10,575.41	44,988.72
IV Expenses:				
a. Cost of materials consumed	2,364.99	2,079.47	2,025.24	9,021.63
b. Purchase of traded goods	3,203.10	2,642.13	2,403.62	9,228.22
c. Changes in inventories of finished goods, stock in trade and work in progress	2.99	(266.80)	(39.33)	(238.77)
d. Employee benefit expenses	1,145.92	981.71	897.42	3,882.04
e. Finance cost	1.22	1.36	1.61	6.12
f. Depreciation & Amortisation Expenses	545.23	617.41	384.45	1,898.78
g. Other Expenses	1,744.06	2,124.50	1,505.04	6,585.40
h. Total Expenses	9,007.51	8,179.78	7,178.05	30,383.42
V Profit before exceptional items and Tax (IV-V)	5,314.26	3,171.18	3,397.36	14,605.30
VI Exceptional items	-	-	-	-
VII Profit Before Tax (V-VI)	5,314.26	3,171.18	3,397.36	14,605.30
VIII Tax Expenses				
(1) Current Tax	948.55	1,014.31	883.63	4,054.79
(2) Deferred Tax	229.46	(0.94)	73.99	319.42
Total Tax Expenses	1,178.01	1,013.37	957.62	4,374.21
IX Net Profit for the period (VII-VIII)	4,136.25	2,157.81	2,439.74	10,231.09
X Other Comprehensive Income/ (Loss) - Net of Income Tax				
A. Items that will not be re-classified to profit or loss				
i) Remeasurements of Defined Benefit Plan	14.05	64.23	4.13	76.60
XI Total Comprehensive Income For The Period (IX+X)	4,150.30	2,222.04	2,443.87	10,307.69
XII Paid up Equity Share Capital (Face value of shares of Rs 2/- each)	1,512.07	1,512.07	1,511.53	1,512.07
XIII Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year				28,048.36
XIV Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share				
(a) Basic (in Rupees)	5.47	2.94	3.23	13.64
(b) Diluted (in Rupees)	5.45	2.93	3.21	13.57



Indhu



Notes :

- 1) This statement has been prepared in accordance with the Companies (Indian Accounting standards) Rules, 2015 ("Ind As") prescribed under Section 133 of the Companies Act, 2013 and other accounting pronouncement generally accepted in India, to the extent applicable.
- 2) The above results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors of the Company at their respective meeting held on 6th August 2018.
- 3) The Other income for the three months period ended 30 June 2018 includes a dividend income of Rs 1648.03 lakhs from 100% foreign subsidiary in Hong Kong which has an impact on the earnings and EPS.
- 4) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 5) The statutory auditors have carried out a limited review of the stand alone results for the quarter ended 30th June 2018.
- 6) Prior year / period figures are regrouped / rearranged wherever necessary.

Place : Chennai
Date 6th August 2018



Dr Sridhar Ganesan
Managing Director



CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (CONSOLIDATED) FINANCIAL RESULTS FOR THE THREE MONTHS ENDED 30th JUNE 2018

Prepared in compliance with the Indian Accounting Standards (Ind - AS)


Particulars	Three Months ended			Financial Year Ended
	30.06.2018	31.03. 2018	30.06.2017	31.03.2018
	(1)	(2)	(3)	(4)
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	INR in lakhs			
Income:				
I Revenue from operations	14,645.99	14341.08	12,351.18	53,984.20
II Other income	160.93	289.86	386.21	1,266.52
III Total Income (I+II)	14,806.92	14630.94	12,737.39	55,250.72
IV Expenses:				
a. Cost of materials consumed	2,364.99	2,079.47	2,025.24	9,021.63
b. Purchase of traded goods	4,041.29	4,406.01	3,364.89	15,035.10
c. Changes in inventories of finished goods, stock in trade and work in progress	2.99	(266.80)	(39.33)	(238.77)
d. Employee benefit expenses	1,152.40	1,013.94	897.42	3,914.27
e. Finance cost	1.22	1.36	1.61	6.12
f. Depreciation & Amortisation Expenses	545.33	617.57	384.45	1,899.50
g. Other Expenses	1,781.28	2,236.57	1,513.04	6,775.04
h. Total Expenses	9,889.50	10,088.12	8,147.32	36,412.89
V Profit before exceptional items and Tax (III-IV)	4,917.42	4,542.82	4,590.07	18,837.83
VI Exceptional items	-	-	-	-
VII Profit Before Tax (V-VI)	4,917.42	4,542.82	4,590.07	18,837.83
VIII Tax Expenses				
(1) Current Tax	948.55	1,014.43	883.63	4,054.91
(2) Deferred Tax	229.46	(0.94)	73.99	319.42
Total Tax Expenses	1,178.01	1,013.49	957.62	4,374.33
IX Net Profit for the period (VII - VIII)	3,739.41	3,529.33	3,632.45	14,463.50
X Other Comprehensive Income - Net of Income Tax				
A. Items that will not be re-classified to profit or loss				
i) Remeasurements of Defined Benefit Plan	14.05	64.23	4.13	76.60
B. Items that will be re-classified to profit or loss				
i) Exchange difference in translating the financial statements of foreign operations	(10.42)	-	-	-
XI Total Comprehensive Income For The Period (IX + X)	3,743.04	3,593.56	3,636.58	14,540.10
XII Profit attributable to:				
Owners of the Company	3,742.90	3,535.78	3,633.32	14,478.77
Non- controlling interests	(3.49)	(6.45)	(0.87)	(15.27)
	3,739.41	3,529.33	3,632.45	14,463.50
XIII Total Comprehensive Income For The Period attributable to				
Owners of the Company	3,746.53	3,600.01	3,637.45	14,555.37
Non- controlling interests	(3.49)	(6.45)	(0.87)	(15.27)
	3,743.04	3,593.56	3,636.58	14,540.10
XIV Paid up Equity Share Capital (Face value of share of Rs 2/- each)	1,512.07	1,512.07	1,511.53	1,512.07
XV Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year				34,871.08
XVI Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share				
(a) Basic (in Rupees)	4.95	4.76	4.81	19.26
(b) Diluted (in Rupees)	4.92	4.74	4.79	19.16



Notes :

- 1) This statement has been prepared in accordance with the Companies (Indian Accounting standards) Rules, 2015 ("Ind As") prescribed under Section 133 of the Companies Act, 2013 and other accounting pronouncement generally accepted in India, to the extent applicable.
- 2) The above results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors of the Company at their respective meeting held on 6th August 2018.
- 3) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 4) The statutory auditors have carried out a limited review of the consolidated results for the quarter ended 30th June 2018.
- 5) Prior year / period figures are regrouped / rearranged wherever necessary.

Place Chennai
Date 6th August 2018



Dr Sridhar Ganesan
Managing Director

